Figure 1
Cullinan Metals Options Lithium Property, Thunder Bay, ON
31. Oktober 2022 09:30 ET | Cullinan Metals Corp.
VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cullinan Metals Corp. (CSE: CMT), (OTC: CMTNF), (FWB: 7KO) ("Cullinan" or the “Company) is pleased to announce that it has entered into...
Cullinan Metals Options a Graphite Property in Quebec
20. Oktober 2022 09:00 ET | Cullinan Metals Corp.
VANCOUVER, British Columbia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cullinan Metals Corp. (CSE: CMT) ("Cullinan" or the “Company”) is pleased to announce that it has entered into an option agreement (the...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
10. Januar 2022 06:30 ET | Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
05. Januar 2022 09:00 ET | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in...
CO-MasterLogo@4x_300 DPI.png
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
04. Januar 2022 07:00 ET | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
16. Dezember 2021 06:30 ET | Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13. Dezember 2021 07:00 ET | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
CemtrexLogo_012018_noTag_final.jpg
Cemtrex Announces Settlement of Class Action Securities Lawsuit & Derivative Actions
17. Oktober 2018 08:45 ET | Cemtrex Inc.
Farmingdale, NY, Oct. 17, 2018 (GLOBE NEWSWIRE) --  –  Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), a world leading technology and manufacturing company, announced today that the Company has agreed to...